Sci Rep:阴茎癌发病率更高的地区患者情况分析

2020-03-03 AlexYang MedSci原创

最近,有研究人员确定了巴西的马拉尼昂州中诊断为阴茎癌的患者的流行病学、组织病理学和临床特征情况,该地区是世界上发病率最高的地区。研究人员在2016年7月到2018年10月之间对116名阴茎癌患者进行了调查。大多数患者居住在乡村地区(57%),从事农业(58%),低水平教育或者没有受过教育(90%),结婚或者处于稳定的关系(74%)。平均年龄为60.4±16.51岁(范围为23-93岁)。研究发现,

最近,有研究人员确定了巴西的马拉尼昂州中诊断为阴茎癌的患者的流行病学、组织病理学和临床特征情况,该地区是世界上发病率最高的地区。

研究人员在2016年7月到2018年10月之间对116名阴茎癌患者进行了调查。大多数患者居住在乡村地区(57%),从事农业(58%),低水平教育或者没有受过教育(90%),结婚或者处于稳定的关系(74%)。平均年龄为60.4±16.51岁(范围为23-93岁)。研究发现,包皮过长占比66%,生殖器卫生不良或者中等占比73%,性传播感染历史占比55%以及恋兽癖占比60%。大多数患者第一次性接触年龄为16.2±2.8岁(10-25岁),75%的性伴侣大于6个月。最常见的初始症状为瘙痒症,大多数患者采取了等待治疗(治疗等待时间均值为18.9个月;范围2-84个月)。人乳头瘤病毒(HPV)相关的组织学特征在62%的患者中出现。大多数患者具有组织学II级或者III级(87%),不小于T2阶段的疾病(84%)和淋巴结疾病(42%)。在96%的患者中进行了阴茎切除术。

最后,研究人员指出,该地区阴茎癌的群体发生率最高,主要由低社会经济状态、高HPV感染发生率和包皮过长的特征。治疗的延迟与高晚期癌症和侵入性外科手术治疗有关。年轻患者的高发病率也是一个突出的特征。

原始出处:

Ciro Bezerra Vieira, Laisson Feitoza, Jaqueline Pinho et al. Profile of patients with penile cancer in the region with the highest worldwide incidence. Sci Rep. 19 Feb 2020

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2079276, encodeId=a39720e9276c8, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Nov 26 18:03:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823614, encodeId=6fa61823614a1, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat May 09 11:03:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799875, encodeId=4abc1e9987525, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Oct 31 07:03:00 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293942, encodeId=f0b4129394281, content=<a href='/topic/show?id=bdf29e54396' target=_blank style='color:#2F92EE;'>#阴茎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97543, encryptionId=bdf29e54396, topicName=阴茎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Mar 05 03:03:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528201, encodeId=331c1528201b8, content=<a href='/topic/show?id=62ca9e55940' target=_blank style='color:#2F92EE;'>#阴茎癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97559, encryptionId=62ca9e55940, topicName=阴茎癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a511911925, createdName=waiwai3034, createdTime=Thu Mar 05 03:03:00 CST 2020, time=2020-03-05, status=1, ipAttribution=)]
    2020-11-26 chenhongpeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=2079276, encodeId=a39720e9276c8, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Nov 26 18:03:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823614, encodeId=6fa61823614a1, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat May 09 11:03:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799875, encodeId=4abc1e9987525, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Oct 31 07:03:00 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293942, encodeId=f0b4129394281, content=<a href='/topic/show?id=bdf29e54396' target=_blank style='color:#2F92EE;'>#阴茎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97543, encryptionId=bdf29e54396, topicName=阴茎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Mar 05 03:03:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528201, encodeId=331c1528201b8, content=<a href='/topic/show?id=62ca9e55940' target=_blank style='color:#2F92EE;'>#阴茎癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97559, encryptionId=62ca9e55940, topicName=阴茎癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a511911925, createdName=waiwai3034, createdTime=Thu Mar 05 03:03:00 CST 2020, time=2020-03-05, status=1, ipAttribution=)]
    2020-05-09 lifestar
  3. [GetPortalCommentsPageByObjectIdResponse(id=2079276, encodeId=a39720e9276c8, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Nov 26 18:03:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823614, encodeId=6fa61823614a1, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat May 09 11:03:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799875, encodeId=4abc1e9987525, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Oct 31 07:03:00 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293942, encodeId=f0b4129394281, content=<a href='/topic/show?id=bdf29e54396' target=_blank style='color:#2F92EE;'>#阴茎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97543, encryptionId=bdf29e54396, topicName=阴茎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Mar 05 03:03:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528201, encodeId=331c1528201b8, content=<a href='/topic/show?id=62ca9e55940' target=_blank style='color:#2F92EE;'>#阴茎癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97559, encryptionId=62ca9e55940, topicName=阴茎癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a511911925, createdName=waiwai3034, createdTime=Thu Mar 05 03:03:00 CST 2020, time=2020-03-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2079276, encodeId=a39720e9276c8, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Nov 26 18:03:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823614, encodeId=6fa61823614a1, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat May 09 11:03:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799875, encodeId=4abc1e9987525, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Oct 31 07:03:00 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293942, encodeId=f0b4129394281, content=<a href='/topic/show?id=bdf29e54396' target=_blank style='color:#2F92EE;'>#阴茎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97543, encryptionId=bdf29e54396, topicName=阴茎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Mar 05 03:03:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528201, encodeId=331c1528201b8, content=<a href='/topic/show?id=62ca9e55940' target=_blank style='color:#2F92EE;'>#阴茎癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97559, encryptionId=62ca9e55940, topicName=阴茎癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a511911925, createdName=waiwai3034, createdTime=Thu Mar 05 03:03:00 CST 2020, time=2020-03-05, status=1, ipAttribution=)]
    2020-03-05 dingxiaobo

    #阴茎#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2079276, encodeId=a39720e9276c8, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Nov 26 18:03:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823614, encodeId=6fa61823614a1, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat May 09 11:03:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799875, encodeId=4abc1e9987525, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Oct 31 07:03:00 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293942, encodeId=f0b4129394281, content=<a href='/topic/show?id=bdf29e54396' target=_blank style='color:#2F92EE;'>#阴茎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97543, encryptionId=bdf29e54396, topicName=阴茎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Mar 05 03:03:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528201, encodeId=331c1528201b8, content=<a href='/topic/show?id=62ca9e55940' target=_blank style='color:#2F92EE;'>#阴茎癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97559, encryptionId=62ca9e55940, topicName=阴茎癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a511911925, createdName=waiwai3034, createdTime=Thu Mar 05 03:03:00 CST 2020, time=2020-03-05, status=1, ipAttribution=)]
    2020-03-05 waiwai3034

相关资讯

阴茎癌眼部转移一例

患者男性,43岁。因右眼疼痛伴视力下降1个月余,而于2015年1月31日入住皖南医学院附属弋矶山医院眼科。

NCCN临床实践指南:阴茎癌(2018.V1)

2018年1月,美国国家综合癌症网络(NCCN)发布了阴茎癌指南2018年第1版,指南主要内容涉及: 指南更新摘要 初级评估,临床诊断 Tis,Ta期疾病初级治疗 T1,T2或更晚期疾病初级治疗 不明显腹股沟淋巴结的管理 体积不大的腹股沟淋巴结的管理 体积较大的腹股沟淋巴结的管理 巨大腹股沟淋巴结的管理 监测时间表 复发性疾病的管理 转移性疾病的管控 手术治疗原则 放射治疗原则 化疗原则 疾病分期

Sci Rep:多维整体分析揭示了阴茎癌驱使候选因子和生物标记

阴茎癌(PeCa)在贫穷和不发达国家中是一个显著的公共健康问题,分子数据生成和它们在阴茎癌(PeCa)中的结合仍旧没有很好的研究。最近,有研究人员利用整体方法学结合基因组范围的拷贝数变异、DNA甲基化、miRNA和mRNA表达分析对20名普通PeCa患者进行了研究分析。研究发现,排名前16个驱使候选因子具有基因组变异并且受一系列的miRNAs调控,包括了hsa-miR-31, hsa-miR-34

NCCN临床实践指南:阴茎癌(2018.V2)

2018年3月,美国国家综合癌症网络(NCCN)发布了阴茎癌指南2018年第1版,指南主要内容涉及: 指南更新摘要 初级评估,临床诊断 Tis,Ta期疾病初级治疗 T1,T2或更晚期疾病初级治疗 不明显腹股沟淋巴结的管理 体积不大的腹股沟淋巴结的管理 体积较大的腹股沟淋巴结的管理 巨大腹股沟淋巴结的管理 监测时间表 复

NCCN临床实践指南:阴茎癌(2019.V1)

2018年12月,美国国家综合癌症网络(NCCN)发布了阴茎癌指南2019年第1版,指南主要内容涉及: 指南更新摘要 初级评估,临床诊断 Tis,Ta期疾病初级治疗 T1,T2或更晚期疾病初级治疗 不明显腹股沟淋巴结的管理 体积不大的腹股沟淋巴结的管理 体积较大的腹股沟淋巴结的管理 巨大腹股沟淋巴结的管理 监测时间表 复发性疾病的管理 转移性疾病的管控 手术治疗原则 放射治疗原则 化疗原则 分期

NCCN临床实践指南:阴茎癌(2020.V1)

2020年1月,美国国家综合癌症网络(NCCN)发布了阴茎癌指南2020年第1版,指南主要内容涉及: 指南更新摘要 初级评估,临床诊断 Tis,Ta期疾病初级治疗 T1,T2或更晚期疾病初级治疗 不明显腹股沟淋巴结的管理 体积不大的腹股沟淋巴结的管理 体积较大的腹股沟淋巴结的管理 巨大腹股沟淋巴结的管理 监测时间表 复发性疾病的管理 转移性疾病的管控 手术治疗原则 放射治疗原则 化疗原则 分期